Sinonasal Histopathological Changes After 12 Months of Dupilumab Treatment in Patients with Chronic Rhinosinusitis with Nasal Polyps
Background/Objectives: Dupilumab blocks the interleukin-4 receptor alpha (IL-4Rα) subunit, thereby inhibiting IL-4- and IL-13-mediated signaling, and is an effective treatment for severe chronic rhinosinusitis with nasal polyps (CRSwNP). This study assessed clinical response and histopathological changes reflecting eos...